Monday, July 06, 2015 3:47:45 PM
Look for NNVC under "Infectious Diseases" section
http://www.iirusa.com/therapeuticareapartnership/presentingcos.xml
The 'Top Projects to Watch' are chosen to present in each therapeutic area, and are hand-picked by a panel of independent experts who screen hundreds of compounds and weigh their potential as future products. Many presenting companies in previous years have gone on to establish major partnerships - Trius, Optimer, QRxPharma, Pearl Therapeutics, Vectura, AVEO, Trophos, and BiPar – just to name a few.
The criteria are:
- Large market, large unmet need, with increasing opportunity
- History of the molecule and drug
- Strong science
- Strong company
- Diversity of indications
- Potential for new opportunities beyond the initial indications
- Multi-level partnering opportunities, i.e., biotech to biotech
as well as pharma to biotech
All companies will present on November 20 and will be available for 1:1 partnering meetings during November 20-21.
Senior level business development and licensing executives from small to large pharmaceutical and biotechnology companies attend Therapeutic Area Partnerships every year.
Whether your goal is to introduce yourself to new customers or to enhance relationships with your current customers, you will have the opportunity to meet with decision-makers face-to-face to showcase your company before, during and after the event. Whatever your budget may be, sponsorship offers a great opportunity to reach the most senior level decision-makers.
We can discuss your goals and objectives and work to design the best sponsorship package for your needs. We will work with you throughout the event to enhance your ROI and to ensure you meet your goals. We have many different sponsorship opportunities that will allow you to show your commitment to the industry and increase your presence and networking opportunities.
Agenda: http://www.iirusa.com/therapeuticareapartnership/agenda.xml
Recent NNVC News
- Form 8-K - Current report • Edgar (US Regulatory) • 08/09/2024 08:30:39 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 08/09/2024 08:05:25 PM
- NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • InvestorsHub NewsWire • 05/02/2024 02:07:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 10/13/2023 08:30:41 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 09/28/2023 08:44:54 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM